SEC Form 5 · accession 0001209191-16-094826
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Perry A Karsen
Officer — see remarks
Period of report
Dec 31, 2015
Accepted (ET)
Feb 2, 2016 · 4:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 22, 2015 | G | 1,000 | $0.00 | D | 65,432 | D | |
| Common Stock | holding | — | — | — | 1,639 | I | 401(k) Plan |
Table II — derivative securities
No Table II lines on this filing.
Remarks
Chief Executive Officer of Celgene Cellular Therapeutics